Vascular BioSciences’ Sepsis Research Wins Award at the 46th Annual Critical Care Congress of the Society of Critical Care Medicine
Hydrocortisone Therapy with CAR Peptide Protects the Injured Endothelial Glycocalyx in Sepsis.
Honolulu, HI, January 22, 2017 – On January 22, 2017, Dr. Kodai Suzuki, M.D. of the Gifu University Graduate School of Medicine presented “Hydrocortisone Therapy with CAR Peptide Protects the Injured Endothelial Glycocalyx in Sepsis” at the Society of Critical Care Medicine’s Annual Congress in Honolulu, Hawaii. The research was granted a silver research snapshot award for demonstrating dedication and innovation to the field of critical care. The research was an international collaboration between VBS Pharmaceuticals Division, Vascular BioSciences, Sanford Burnham Prebys Medical Discovery Institute, and the Department of Emergency and Disaster Medicine, Gifu University Graduate School of Medicine in Gifu, Japan.
The research found a significant survival benefit by co-administering CAR peptide with low dose hydrocortisone in an LPS-mouse model of sepsis. Also included in the presentation were striking scanning electron microscope (SEM) images of injured lung, liver, and kidney endothelium and endothelial glycocalyx, as well as the observed marked attenuation of the multi-organ endothelial damage by the CAR plus low dose hydrocortisone combination therapy.
Vascular BioSciences CEO and co-author David Mann commented, “We are honored that the fruits our sepsis collaboration with Drs. Okada and Suzuki at the Gifu University Graduate School of Medicine in Japan are being recognized by the Society of Critical Care Medicine for its contribution to finding a cure for this often-fatal condition.”
About Vascular BioSciences
Vascular BioSciences, a diversified biomedical company with operations in California and North Carolina, provides targeted solutions for serious diseases in order to enhance and prolong human life.
Vascular BioSciences makes interventional catheters to obtain endoarterial biopsies, provides molecular diagnostic services, and through its majority owned subsidiary VBS Pharmaceuticals, develops targeted therapeutics for patients with difficult-to-treat diseases.
For more information about VBS is available at www.vascularbiosciences.com/
For more information, please contact firstname.lastname@example.org